New Online Social Network, BioMedExperts, to Improve Collaboration Among Medical Researchers

Collexis Holdings, Inc. (OTCBB: CLXS), a leading developer of high definition search and knowledge discovery software, announced the debut of BioMedExperts - the first online social network of its kind to improve collaboration among researchers and therefore advance medical science. Collexis launched the new service with more than 1.4 million pre-generated profiles of its expected users from across 120 countries and expects to grow by another two million profiles over the next few months.

An agreement with Dell Healthcare and Life Sciences helped make BioMedExperts possible. Dell supplied the computer hardware for the service and will help market BioMedExperts.

"The ability for researchers to collaborate across scientific disciplines is becoming more and more critical," said James Coffin, Ph.D., vice president and general manager of Dell Healthcare and Life Sciences. "By connecting biologists, chemists, clinical researchers and other scientists from across the globe, BioMedExperts can play a key role in enabling a new wave of modern science and have tremendous impact on progress in biomedical research."

The new service will allow life sciences professionals to connect with each other, share data, collaborate more efficiently and conduct deep research across thousands of sources.

"Where first generation social networks like Facebook and LinkedIn require users to enter data, BioMedExperts is a life science open platform that goes to the next level – it continuously captures the research activity of experts worldwide, serving as a definitive source to identify relationships to others within the community, either by topic or geography," said Bill Kirkland, CEO of Collexis. When researchers log on to the service, which is entirely free, they will have access to approximately 12 million pre-established network connections, automatically generated from more than 6 million scientific publications from 6,500 journals. BioMedExperts encompasses almost every published researcher in the biomedical sciences field worldwide.

Searching by name, keyword or location, scientists can quickly see their own "network" of co-authors ...and even co-authors of their co-authors. The site makes it easy for researchers and scientists to analyze all associated professional connections within the network as well as find new potential research partners, co-authors, etc.

BioMedExperts includes tools that allow users to:

  • Search the network of profiles and articles by expert name or keyword and analyze the profiles of more than 1.4 million scientists by expertise, region and more
  • Customize their own profiles
  • Communicate with other members of BioMedExperts – users can invite others to their own personal network and email experts from within the entire BioMedExperts community to cultivate and grow professional affiliations
  • Set up article alerts – users can receive alerts on new articles by topic or by name (for example, users can easily track articles published by co-authors

BioMedExperts is based on Collexis' proprietary Fingerprint technology, an enterprise research tool that serves as the basis of search and retrieval solutions for such leading organizations as Harvard University, Johns Hopkins, the Mayo Clinic and The National Institutes of Health.

Kirkland added that BioMedExperts is the first in a series of professional social networks that the company plans to introduce over the next couple of years that utilizes the proprietary technology.

For further information, please visit:
http://www.biomedexperts.com

About Collexis Holdings, Inc.
Named a Trend-Setting product of 2007 by KMWorld, Collexis Holdings, Inc., a leading developer of high definition search and knowledge discovery software since 1999, is headquartered in Columbia, South Carolina (USA), with operations in Geldermalsen, The Netherlands and Cologne, Germany. Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Merck & Co.; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. For more information, please visit www.collexis.com.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...